Eli Lilly has launched Lormalzi, a monthly treatment for early Alzheimer’s disease, in India. The therapy targets amyloid plaques and is set to be available this month. Positioned as part of the company’s broader push in specialty medicines, Lormalzi comes with a steep price tag of ₹91,688 per vial. The move signals rising focus on Alzheimer’s innovation in India.
A prescription-only intravenous Alzheimer’s treatment has launched in India at Rs 91,688 for a 350 mg vial. The monthly therapy can be given for up to 18 months, making the total cost potentially steep for many patients. The drug targets the underlying disease process linked to amyloid plaque buildup and neurofibrillary tangles in the brain.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
